Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06100874 · ClinicalTrials.gov registry record · Phase 2
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
A Phase 2 study of Breast Cancer Female and Breast Cancer Metastatic, sponsored by Adrienne G. Waks.
- Active
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT06100874 is a Phase 2 study of Breast Cancer Female and Breast Cancer Metastatic that is active but no longer recruiting, run by Adrienne G. Waks. The registered enrollment target is 28 participants, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06100874, a Phase 2 study of Breast Cancer Female and Breast Cancer Metastatic, is active but no longer recruiting, sponsored by Adrienne G. Waks.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: * Sacituzumab govitecan (a type of antibody-drug conjugate) * Trastuzumab (Herceptin) (a type of monoclonal antibody) * Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) * Trastuzumab biosimilar drug
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Sacituzumab Govitecan
- DRUG Trastuzumab and Hyaluronidase-oysk
Study Locations (4)
Massachusetts
- Dana Farber Cancer Institite - Boston
- DFCI @ South Shore Hospital - South Weymouth
Florida
- Miami Cancer Institute at Baptist Health - Miami
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06100874
The ClinicalTrials.gov registry entry for NCT06100874 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (96% lower). The listed sponsor is Adrienne G. Waks, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer Female appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.
NCT06100874 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06100874 about?
NCT06100874 is a clinical study titled "A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)". This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: * Sacituzumab govitecan (a...
What is the current status of trial NCT06100874?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-11-20. Estimated completion is 2027-11-30.
What conditions does trial NCT06100874 study?
This clinical trial studies the following conditions: Breast Cancer Female, Breast Cancer Metastatic, Her 2 Positive Breast Cancer.
What interventions are being tested in trial NCT06100874?
The interventions under investigation include: Trastuzumab (DRUG), Sacituzumab Govitecan (DRUG), Trastuzumab and Hyaluronidase-oysk (DRUG).
Who is sponsoring clinical trial NCT06100874?
This trial is sponsored by Adrienne G. Waks, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06100874 being conducted?
This trial has 4 study locations across Florida, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Microbiome and Association With Implant Infections
RECRUITING · Phase 2
-
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RECRUITING · Phase 2
-
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
RECRUITING · Phase 2
-
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.